As the Foundation continues to break new ground, particularly in the areas of new drug development and in Survivorship, we’re thrilled to announce several additions to our Board of Directors and advisory boards intended to build strength in those areas. Each of these individuals brings to the organization deep subject-matter expertise, invaluable perspective, and a wholehearted dedi
cation to this cause. Below is a brief thumbnail introducing each of them. We are grateful for their service and are looking forward to working with them to take the organization to new heights.
Paul Feldman, PhD – Board of Directors
Paul is an experienced drug developer with three decades of experience in the pharmaceutical industry. He is currently Head of Discovery and Translational Medicine for the biotechnology company Intarcia Therapeutics, which he joined following the acquisition of Phoundry Pharmaceuticals, where he was a co-founder and CEO. Previously, he held positions of increasing responsibility at GlaxoSmithKline, where he led drug discovery and early development teams, ultimately serving as a senior vice president and head of GlaxoSmithKline’s Research Triangle Park site. Paul received a BS in chemistry from Duke University and a PhD in organic chemistry from the University of California, Berkeley. His passion for our mission comes from personal experience as the family member of a chordoma patient.
Sue Mahony, PhD, MBA – Board of Directors
Sue is a pharmaceutical and life sciences executive with three decades of experience leading global organizations. Prior to her retirement in 2018, as senior vice president and president of Lilly oncology, Sue led the development and commercialization of Lilly’s oncology portfolio globally, launching new products to treat breast, lung, colorectal, and stomach cancers. Prior to this, Sue held senior leadership roles in product development, human resources, general management, and sales and marketing for Lilly, Bristol-Myers Squibb, Amgen, and Schering-Plough. Sue is currently an independent board director for Assembly Biosciences, Zymeworks, Horizon Therapeutics, Vifor Pharma, Cereius, and Altis Biosystems. Sue earned her BSc in Pharmacy and a PhD in Oncology from the University of Aston in the UK. She also received her MBA from the London School of Business.
Charles Lin, PhD – Scientific Advisory Board
Charles is a cancer biologist and an expert in the role that transcription factors play in driving cancer. He is currently the Vice President of Biology at Kronos Bio, a company developing novel cancer therapeutics targeting the processes that regulate gene expression. Previously, he was an Assistant Professor in the Department of Molecular and Human Genetics and the Co-Director of the Therapeutic Innovation Center at Baylor College of Medicine in Houston. There, his lab made important contributions to understanding brachyury’s role in chordoma, and created research tools that are being used in the development of drugs against brachyury. He received a BS in Biology and Physics from Duke University and a PhD in Computational and Systems Biology from the Massachusetts Institute of Technology.
Megan Stewart – Community Advisory Board
When Megan’s husband, Joe, was diagnosed with sacral chordoma in 2016, she was his primary caregiver and a fierce advocate throughout his diagnostic odyssey and treatment. Through this experience, Megan became passionate about supporting other patients and their families through their own journeys with chordoma. This ultimately led her to return to school and obtain a certificate in Patient Advocacy from UCLA in December 2019. Megan also holds a bachelor’s degree in International Politics and a master’s degree in International Finance from Georgetown University’s School of Foreign Service. Megan and Joe live in Atlanta, Georgia, with their two teenagers. There, she is an active member of the local community, including serving as the president of the Alumni Association at Marist School. Since Joe’s diagnosis, Megan has been an active member of the Chordoma Foundation’s capital campaign committee and worked on fundraising and awareness initiatives to support the Foundation’s goals.
